Neurodegenerative diseases (NDs) are considered heterogeneous disorders characterized by progressive pathological changes in neuronal systems. Transcription factors are protein molecules that are important in regulating the expression of genes. Although the clinical manifestations of NDs vary, the pathological processes appear similar with regard to neuroinflammation, oxidative stress, and proteostasis, to which, as numerous studies have discovered, transcription factors are closely linked. In this review, we summarized and reviewed the roles of transcription factors in NDs, and then we elucidated their functions during pathological processes, and finally we discussed their therapeutic values in NDs.
AkerfeltMMorimotoRISistonenL.2010. Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol11(8):545–55.
2.
AlbensiBCMattsonMP. 2000. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse35(2):151–9.
3.
AnckarJSistonenL.2007. Heat shock factor 1 as a coordinator of stress and developmental pathways. In: CsermelyPVíghL, editors. Molecular aspects of the stress response: chaperones, membranes and networks. New York, NY: Springer. pp. 78–88.
4.
AndersonMJViarsCSCzekaySCaveneeWKArdenKC. 1998. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics47(2):187–99.
5.
Barranco QuintanaJLAllamMFDel CastilloASNavajasRF-C.2009. Parkinson’s disease and tea: a quantitative review. J Am Coll Nutr28(1):1–6.
6.
BergmanOHåkanssonAWestbergLNordenströmKCarmine BelinASydowO, and others. 2010. PITX3 polymorphism is associated with early onset Parkinson’s disease. Neurobiol Aging31(1):114–7.
7.
BrennanMSMatosMFRichterKELiBScannevinRH. 2017. The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes. Sci Rep [Internet]7:42054. doi:10.1038/srep42054
8.
CamandolaSMattsonMP. 2007. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets11(2):123–32.
9.
CaoGSuPZhangSGuoLZhangHLiangY, and others. 2016. Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells. Eur J Pharmacol793:101–8.
10.
CarrCSSharpPA. 1990. A helix-loop-helix protein related to the immunoglobulin E box-binding proteins. Mol Cell Biol10(8):4384–8.
ChakrabartiAChenAWVarnerJD. 2011. A review of the mammalian unfolded protein response. Biotechnol Bioeng108(12):2777–93.
13.
ChangCChiangMTohEK-WChangC-FHuangT.2013. Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. FEBS Lett587(6):575–82.
14.
ChenLLiuB.2017. Review Article Relationships between stress granules, oxidative stress, and neurodegenerative diseases. Oxid Med Cell Longev2017:1809592.
15.
ChongJATapia-RamírezJKimSToledo-AralJJZhengYBoutrosMC, and others. 1995. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell80(6):949–57.
16.
ChristensenMAZhouWQingHLehmanAPhilipsenSSongW.2004. Transcriptional regulation of BACE1, the β-amyloid precursor protein β-secretase, by Sp1. Mol Cell Biol24(2):865–74.
17.
CisséMDuplanELorivelTDunysJBauerCMecklerX, and others. 2016. The transcription factor XBP1s restores hippocampal synaptic plasticity and memory by control of the Kalirin-7 pathway in Alzheimer model. Mol Psychiatry22(11):1562–75.
18.
CitronBASaykallyJNCaoCDennisJSRunfeldtMArendashGW. 2015. Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer’s disease. Am J Neurodegener Dis4(2):40–8.
19.
CohenTJHwangAWUngerTTrojanowskiJQLeeVM. 2012. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J31(5):1241–52.
20.
CornejoVHHetzC.2013. The unfolded protein response in Alzheimer’s disease. Semin Immunopathol35(3):277–92.
21.
CoulsonJM. 2005. Transcriptional regulation: cancer, neurons and the REST. Curr Biol15(7):R665–8.
22.
DavieCA. 2008. A review of Parkinson’s disease. Br Med Bull86:109–27.
23.
DayaluPAlbinRL. 2015. Huntington disease: pathogenesis and treatment. Neurol Clin33(1):101–14.
24.
de LauLMBretelerMM. 2006. Epidemiology of Parkinson’s disease. Lancet Neurol5(6):525–35.
25.
DengH-XChenWHongS-TBoycottKMGorrieGHSiddiqueN, and others. 2011. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature477(7363):211–5.
26.
DluzenDLiGTaceloskyDMoreauMLiuDX. 2011. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner. J Biol Chem286(9):7705–13.
27.
DocagneFGabrielCLebeurrierNLesnéSHommetYPlawinskiL, and others. 2004. Sp1 and Smad transcription factors co-operate to mediate TGF-β-dependent activation of amyloid-β precursor protein gene transcription. Biochem J383(pt 2):393–9.
28.
DoiMNakajimaYOkanoTFukadaY. 2001. Light-induced phase-delay of the chicken pineal circadian clock is associated with the induction of cE4bp4, a potential transcriptional repressor of cPer2 gene. Proc Natl Acad Sci U S A98(14):8089–94.
29.
DoiMOkanoTYujnovskyISassone-CorsiPFukadaY. 2004. Negative control of circadian clock regulator E4BP4 by casein kinase 1epsilon-mediated phosphorylation. Curr Biol14(11):975–80.
30.
DuXWangJZhuHRinaldoLLamarK-MPalmenbergAC, and others. 2013. Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6. Cell154(1):118–33.
31.
DurrAGargiuloMFeingoldJ.2012. The presymptomatic phase of Huntington disease. Rev Neurol (Paris)168(11):806–8.
32.
ElbrechtAChenYCullinanCAHayesNLeibowitzMdMollerDE, and others. 1996. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun224(2):431–7.
33.
FarmerSR. 2003. The forkhead transcription factor Foxo1: a possible link between obesity and insulin resistance. Mol Cell11(1):6–8.
34.
Fernandez-FernandezMRFerrerILucasJJ. 2011. Impaired ATF6α processing, decreased Rheb and neuronal cell cycle re-entry in Huntington’s disease. Neurobiol Dis41(1):23–32.
35.
FraserPE. 2017. Tribbles pseudokinase 3 induces both apoptosis and autophagy in amyloid-β-induced neuronal death. J Biol Chem292(7):2571–85.
36.
FuchsJMuellerJCLichtnerPSchulteCMunzMBergD, and others. 2009. The transcription factor PITX3 is associated with sporadic Parkinson’s disease. Neurobiol Aging30(5):731–8.
GaoLSheHLiWZengJZhuJJonesDP, and others. 2014. Oxidation of survival factor MEF2D in neuronal death and Parkinson’s disease. Antioxid Redox Signal20(18):2936–48.
39.
GasserEJohannssenHCRülickeTZeilhoferHUStoffelM.2016. Foxa1 is essential for development and functional integrity of the subthalamic nucleus. Sci Rep6:38611.
40.
Gaweda-WalerychKZekanowskiC.2013a. The impact of mitochondrial DNA and nuclear genes related to mitochondrial functioning on the risk of Parkinson’s disease. Curr Genomics14(8):543–59.
41.
Gaweda-WalerychKZekanowskiC.2013b. Integrated pathways of parkin control over mitochondrial maintenance—relevance to Parkinson’s disease pathogenesis. Acta Neurobiol Exp (Wars)73:199–224.
42.
GidalevitzTBen-ZviAHoKHBrignullHRMorimotoRI. 2006. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science311(5766):1471–4.
43.
GilmoreTD. 2006. Introduction to NF-κB: players, pathways, perspectives. Oncogene25(51):6680–4.
44.
GoodeAReaSSultanaMShawBSearleMSLayfieldR.2016. ALS-FTLD associated mutations of SQSTM1 impact on Keap1-Nrf2 signalling. Mol Cell Neurosci76:52–8.
45.
GreeneMEBlumbergBMcBrideOWYiHFKronquistKKwanK, and others. 1995. Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr4(4–5):281–99.
46.
HaiTWLiuFCoukosWJGreenMR. 1989. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev3(12B):2083–90.
47.
HarjesPWankerEE. 2003. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci28(8):425–33.
48.
HashimotoMHsuLJXiaYTakedaASiskASundsmoM, and others. 1999. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport10(4):717–21.
49.
HernándezIHTorres-PerazaJSantos-GalindoMRamos-MorónEFernández-FernándezMRPérez-ÁlvarezMJ, and others. 2017. The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington’s disease. Acta Neuropathol134(6):839–50.
50.
HetzC. 2012. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol13(2):89–102.
51.
HetzCMartinonFRodriguezDGlimcherLH. 2011. The unfolded protein response: integrating stress signals through the stress sensor IRE1α. Physiol Rev91(4):1219–43.
52.
HetzCMollereauB.2014. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci15(4):233–49.
53.
HunotSBruggBRicardDMichelPPMurielMPRubergM, and others. 1997. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A94(14):7531–6.
54.
ItohKWakabayashiNKatohYIshiiTO’ConnorTYamamotoM.2003. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells8(4):379–91.
55.
IzumiSSaitoAKanemotoSKawasakiNAsadaRIwamotoH, and others. 2012. The endoplasmic reticulum stress transducer BBF2H7 suppresses apoptosis by activating the ATF5-MCL1 pathway in growth plate cartilage. J Biol Chem287(43):36190–200.
56.
JacobsFMJSmitsSMNoorlanderCWvon OerthelLvan der LindenAJABurbachJPH, and others. 2007. Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development134(14):2673–84.
57.
JohnsonDAJohnsonJA. 2015. Nrf2–a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med88(pt B):253–67.
58.
JopeRSChengYLowellJAWorthenRJSitbonYHBeurelE.2016. Stressed and in flamed, can GSK3 be blamed ?Trends Biochem Sci42(3):180–92.
59.
JoshiGJohnsonJA. 2012. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov7(3):218–29.
60.
JunghansDChauvetSBuhlerEDudleyKSykesTHendersonCE. 2004. The CES-2-related transcription factor E4BP4 is an intrinsic regulator of motoneuron growth and survival. Development131(18):4425–34.
KalshekerNA. 1996. Alpha 1-antichymotrypsin. Int J Biochem Cell Biol28(9):961–4.
63.
KaltschmidtBUherekMVolkBBaeuerlePAKaltschmidtC.1997. Transcription factor NF-kappaB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A94(6):2642–7.
64.
KannikeKSeppMZuccatoCCattaneoETimmuskT.2014. Forkhead transcription factor FOXO3a levels are increased in Huntington disease because of overactivated positive autofeedback loop. J Biol Chem289:32845–57.
65.
KapogiannisDMattsonMP. 2011. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease. Lancet Neurol10(2):187–98.
66.
KarinM. 1990. Too many transcription factors: positive and negative interactions. New Biol2(2):126–31.
67.
KeiserMSKordowerJHGonzalez-AlegrePDavidsonBL. 2015. Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain138(pt 12):3555–66.
68.
KenslerTWWakabayashiNBiswalS.2007. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol47:89–116.
69.
KhoshnanAKoJWatkinEEPaigeLAReinhartPHPattersonPH. 2004. Activation of the IkappaB kinase complex and nuclear factor-κB contributes to mutant huntingtin neurotoxicity. J Neurosci24(37):7999–8008.
70.
KiernanMCVucicSCheahBCTurnerMREisenAHardimanO, and others. 2011. Amyotrophic lateral sclerosis. Lancet377(9769):942–55.
71.
KiffinRChristianCKnechtECuervoAM. 2004. Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell15(11):4829–40.
72.
KimJInoueKIshiiJVantiWBVoronovSVMurchisonE, and others. 2007. A microRNA feedback circuit in midbrain dopamine neurons. Science317(5842):1220–4.
73.
KimYEHospFMannMHayer-HartlMHartlFU. 2016. Soluble oligomers of polyQ-expanded huntingtin target a multiplicity of key cellular factors article soluble oligomers of polyQ-expanded huntingtin target a multiplicity of key cellular factors. Mol Cell63(6):951–64.
74.
KoLJEngelJD. 1993. DNA-binding specificities of the GATA transcription factor family. Mol Cell Biol13(7):4011–22.
75.
KornbergRD. 2007a. The molecular basis of eukaryotic transcription. Proc Natl Acad Sci U S A104(32):12955–61.
76.
KornbergRD. 2007b. The molecular basis of eukaryotic transcription. Proc Natl Acad Sci U S A104(32):12955–61.
77.
KramerNJCarlomagnoYZhangYAlmeidaSCookCNGendronTF, and others. 2016. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science353(6300):708–12.
78.
KumstaCChangJTSchmalzJHansenM.2017. Hormetic heat stress and HSF-1 induce autophagy to improve survival and proteostasis in C. elegans. Nat Commun8:14337.
79.
La SpadaAR. 2012. PPARGC1A/PGC-1α, TFEB and enhanced proteostasis in Huntington disease: defining regulatory linkages between energy production and protein-organelle quality control. Autophagy8(12):1845–7.
80.
LatchmanDS. 1997. Transcription factors: an overview. Int J Biochem Cell Biol29(12):1305–12.
81.
LechlerMCCrawfordEDGrohNTrinidadJCBurlingameALDavidDC, and others. 2017. Reduced insulin/IGF-1 signaling restores the dynamic properties of key stress granule proteins during aging article reduced insulin/IGF-1 signaling restores the dynamic properties of key stress granule proteins during aging. Cell Rep18:454–67.
82.
LeeTIYoungRA. 2000. Transcription of eukaryotic protein-coding genes. Annu Rev Genet34:77–137.
83.
LesageSBriceA.2009. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet18:R48–59.
84.
LeWittPA. 2015. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov Disord30:64–72.
85.
LiouHCEddyRShowsTLisowska-GrospierreBGriscelliCDoyleC, and others. 1991. An HLA-DR alpha promoter DNA-binding protein is expressed ubiquitously and maps to human chromosomes 22 and 5. Immunogenetics34(5):286–92.
86.
LuTAronLZulloJPanYKimHChenY, and others. 2014. REST and stress resistance in ageing and Alzheimer’s disease. Nature507:448–54.
87.
LuTPanYKaoS-YLiCKohaneIChanJ, and others. 2004. Gene regulation and DNA damage in the ageing human brain. Nature429(6994):883–91.
88.
LukiwWJRogaevEIWongLVaulaGMcLachlanDRSt George HyslopP.1994. Protein-DNA interactions in the promoter region of the amyloid precursor protein (APP) gene in human neocortex. Brain Res Mol Brain Res22(1–4):121–31.
89.
MaleVNisoliIGascoyneDMBradyHJM. 2012. E4BP4: an unexpected player in the immune response. Trends Immunol33(2):98–102.
90.
ManolopoulosKNKlotzL-OKorstenPBornsteinSRBarthelA.2010. Linking Alzheimer’s disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry15(11):1046–52.
91.
MarsdenJHarrisC.2011. Cerebellar ataxia: pathophysiology and rehabilitation. Clin Rehabil25(3):195–216.
92.
MatusSLopezEValenzuelaVNassifMHetzC.2013. Functional contribution of the transcription factor ATF4 to the pathogenesis of amyotrophic lateral sclerosis. PLoS One8(7):e66672.
93.
MaxwellPSalnikowK.2004. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther3(1):29–35.
94.
McMahonMItohKYamamotoMHayesJD. 2003. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem278(24):21592–600.
95.
McNaughtKSJennerP.2001. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett297:191–4.
96.
MichalikLAuwerxJBergerJPChatterjeeVKGlassCKGonzalezFJ, and others. 2006. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev58(4):726–41.
97.
MitchellPJTjianR.1989. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science245(4916):371–8.
98.
MitsuiSYamaguchiSMatsuoTIshidaYOkamuraH.2001. Antagonistic role of E4BP4 and PAR proteins in the circadian oscillatory mechanism. Genes Dev15(8):995–1006.
99.
MoorsTEHoozemansJJMIngrassiaABeccariTParnettiLChartier-HarlinM-C, and others. 2017. Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease. Mol Neurodegener12(1):11.
100.
MurdochJDRostoskyCMGowrisankaranSBonnSRaimundoNMilosevicI, and others. 2016. Endophilin-A deficiency induces the Foxo3a-Fbxo32 network in the brain and causes dysregulation of autophagy and the ubiquitin-proteasome system. Cell Rep17(4):1071–86.
101.
NakamuraKJeongSYUchiharaTAnnoMNagashimaKNagashimaT, and others. 2001. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet10(14):1441–8.
102.
NaranjoJRZhangHVillarDGonzálezPDopazoXMMorón-OsetJ, and others. 2016. Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease. J Clin Invest126(2):627–38.
103.
NeefDWJaegerAMThieleDJ. 2011. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov10(12):930–44.
104.
NijholtDATDe KimpeLElfrinkHLHoozemansJJMScheperW. 2011. Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr Med Chem18(16):2459–76.
105.
NikolovDBBurleySK. 1997. RNA polymerase II transcription initiation: a structural view. Proc Natl Acad Sci U S A94(1):15–22.
106.
NixonRA. 2013. The role of autophagy in neurodegenerative disease. Nat Med19(8):983–97.
107.
NunesITovmasianLTSilvaRMBurkeREGoffSP. 2003. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A100(7):4245–50.
108.
ObesoJARodriguez-OrozMCGoetzCGMarinCKordowerJHRodriguezM, and others. 2010. Missing pieces in the Parkinson’s disease puzzle. Nat Med16(6):653–61.
109.
OrrHT. 2012. Cell biology of spinocerebellar ataxia. J Cell Biol197(2):167–77.
110.
PajaresMCuadradoARojoAI. 2017. Redox biology modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biol11:543–53.
111.
ParkSHChoiW-SYoonS-YAhnYSOhYJ. 2004. Activation of NF-κB is involved in 6-hydroxydopamine—but not MPP+-induced dopaminergic neuronal cell death: its potential role as a survival determinant. Biochem Biophys Res Commun322(3):727–33.
112.
PengCFanSLiXFanXMingMSunZ, and others. 2007. Overexpression of pitx3 upregulates expression of BDNF and GDNF in SH-SY5Y cells and primary ventral mesencephalic cultures. FEBS Lett581(7):1357–61.
113.
PtashneMGannA.1997. Transcriptional activation by recruitment. Nature386(6625):569–77.
114.
QuerfurthHWJiangJXiaWSelkoeDJ. 1999. Enhancer function and novel DNA binding protein activity in the near upstream betaAPP gene promoter. Gene232(1):125–41.
115.
RamseyCPGlassCAMontgomeryMBLindlKARitsonGPChiaLA, and others. 2007. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol66(1):75–85.
116.
RoederRG. 1996. The role of general initiation factors in transcription by RNA polymerase II. Trends Biochem Sci21(9):327–35.
117.
RosenDRSappPO’ReganJMcKenna-YasekDSchlumpfKSHainesJL, and others. 1994. Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromosome 21 microsatellite DNA markers. Am J Med Genet51(1):61–9.
118.
RubinszteinDCLeggoJCrowTJDeLisiLEWalshCJainS, and others. 1996. Analysis of polyglutamine-coding repeats in the TATA-binding protein in different human populations and in patients with schizophrenia and bipolar affective disorder. Am J Med Genet67(5):495–8.
119.
RyuHLeeJZamanKKubilisJFerranteRJRossBD, and others. 2003. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci23(9):3597–606.
120.
SadoMYamasakiYIwanagaTOnakaYIbukiTNishiharaS, and others. 2009. Protective effect against Parkinson’s disease-related insults through the activation of XBP1. Brain Res1257:16–24.
121.
Sadri-VakiliGChaJ-HJ. 2006. Mechanisms of disease: histone modifications in Huntington’s disease. Nat Clin Pract Neurol2:330–8.
122.
SalaGArosioAStefanoniGMelchiondaLRivaCMarinigD, and others. 2013. Rotenone upregulates alpha-synuclein and myocyte enhancer factor 2D independently from lysosomal degradation inhibition. Biomed Res Int2013:846725.
123.
SardielloMPalmieriMdi RonzaAMedinaDLValenzaMGennarinoVA, and others. 2009. A gene network regulating lysosomal biogenesis and function. Science325(5939):473–7.
124.
ScherzerCRGrassJALiaoZPepivaniIZhengBEklundAC, and others. 2008. GATA transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A105(31):10907–12.
125.
SchonrockNHumphreysDTPreissTGötzJ.2012. Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β. J Mol Neurosci46(2):324–35.
126.
SelkoeDJHardyJ.2016. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med8(6):595–608.
127.
SeminaEVFerrellREMintz-HittnerHABitounPAlwardWLMReiterRS, and others. 1998. A novel homeobox gene PITX3 is mutated in families with autosomal-dominant cataracts and ASMD. Nat Genet19(2):167–70.
128.
SheHYangQShepherdKSmithYMillerGTestaC, and others. 2011. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest121(3):930–40.
129.
ShiCViccaroKLeeH-GShahK.2016. Cdk5-Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer’s disease models. J Cell Sci129(9):1815–30.
130.
SingletonABFarrerMJohnsonJSingletonAHagueSKachergusJ, and others. 2003. α-Synuclein locus triplication causes Parkinson’s disease. Science302(5646):841.
131.
SivanandamTMThakurMK. 2012. Traumatic brain injury: a risk factor for Alzheimer’s disease. Neurosci Biobehav Rev36(5):1376–81.
132.
SkoogIGustafsonD.2006. Update on hypertension and Alzheimer’s disease. Neurol Res28(6):605–11.
133.
SmidtMPSmitsSMBouwmeesterHHamersFPTvan der LindenAJAHellemonsAJCGM, and others. 2004. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development131(5):1145–55.
134.
SuBLiuHWangXChenSGSiedlakSLKondoE, and others. 2009. Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener4:32.
135.
SunXHeGQingHZhouWDobieFCaiF, and others. 2006. Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A103(49):18727–32.
136.
SykiotisGPBohmannD.2010. Stress-activated Cap’n’collar transcription factors in aging and human disease. Sci Signal3(112):re3.
137.
TamaiSImaizumiKKurabayashiNNguyenMDAbeTInoueM, and others. 2014. Neuroprotective role of the basic leucine zipper transcription factor NFIL3 in models of amyotrophic lateral sclerosis. J Biol Chem289:1629–38.
138.
TirantiVRossiERuiz-CarrilloARossiGRocchiMDiDonatoS, and others. 1995. Chromosomal localization of mitochondrial transcription factor A (TCF6), single-stranded DNA-binding protein (SSBP), and endonuclease G (ENDOG), three human housekeeping genes involved in mitochondrial biogenesis. Genomics25(2):559–64.
139.
TsouWQiblawiSHHoskingRRGomezCMTodiSV. 2016. Polyglutamine length-dependent toxicity from α1ACT in Drosophila models of spinocerebellar ataxia type 6. Biol Open5(12):1770–5.
140.
TsujimotoANyunoyaHMoritaTSatoTShimotohnoK.1991. Isolation of cDNAs for DNA-binding proteins which specifically bind to a tax-responsive enhancer element in the long terminal repeat of human T-cell leukemia virus type I. J Virol65:1420–6.
141.
TsunemiTAsheTDMorrisonBESorianoKRAuJRoqueRAV, and others. 2012. PGC-1α rescues Huntington’s disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med4(142):142ra97.
142.
UgolinoJJiYJConchinaKChuJNirujogiRS. 2016. Loss of C9orf72 enhances autophagic activity via deregulated mTOR and TFEB signaling. PLoS Genet12(11):e1006443
143.
Ugun-KlusekATathamMHElkharazJConstantin-TeodosiuDLawlerKMohamedH, and others. 2017. Continued 26S proteasome dysfunction in mouse brain cortical neurons impairs autophagy and the Keap1-Nrf2 oxidative defence pathway. Cell Death Dis8(1):e2531.
144.
ValeraESpencerBMasliahE.2016. Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and Tau for the treatment of neurodegenerative disorders. Neurotherapeutics13:179–89.
145.
ValerioABoroniFBenareseMSarnicoIGhisiVBrescianiLG, and others. 2006. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci23(7):1711–20.
146.
VidalRLFigueroaACourtFAThielenPMolinaCWirthC, and others. 2012. Targeting the UPR transcription factor XBP1 protects against Huntington’s disease through the regulation of FoxO1 and autophagy. Hum Mol Genet21(10):2245–62.
147.
VihervaaraASistonenL.2014. HSF1 at a glance. J Cell Sci127(pt 2):261–6.
WangBCaiZLuFLiCZhuXSuL, and others. 2014. Destabilization of survival factor MEF2D mRNA by neurotoxin in models of Parkinson’s disease. J Neurochem130(5):720–8.
YaoLLiWSheHDouJJiaLHeY, and others. 2012. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. J Biol Chem287:34246–55.
153.
ZhangJShiRLiHXiangYXiaoLHuM.2016. Antioxidant and neuroprotective effects of Dictyophora indusiata polysaccharide in Caenorhabditis elegans. J Ethnopharmacol192:413–22.
154.
ZhangXZhouKWangRCuiJLiptonSALiaoF-F, and others. 2007. Hypoxia-inducible factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and β-amyloid generation. J Biol Chem282(15):10873–80.
155.
ZouJGuoYGuettoucheTSmithDFVoellmyR.1998. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell94(4):471–80.
